Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses-Reference-Cited by-同舟云学术

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

Published:2017-08-12 Issue:5 Volume:12 Page:643-654
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Gupta Neeraj^ORCID,Yang Huyuan,Hanley Michael J.,Zhang Steven,Liu Rachael,Kumar Shaji,Richardson Paul G.,Skacel Tomas,Venkatakrishnan Karthik

Funder

Millennium Pharmaceuticals, Inc.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s11523-017-0524-3/fulltext.html

Reference36 articles.

1. Richardson PG, Moreau P, Laubach JP, et al. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. Future Oncol. 2015;11(8):1153–68.

2. Millennium Pharmaceuticals Inc. NINLARO® (ixazomib) capsules, for oral use. Prescribing information, November 2016. http://www.ninlaro.com/downloads/prescribing-information.pdf . Accessed 24 July 2017.

3. Takeda Pharma AS. NINLARO® (ixazomib). Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003844/WC500217620.pdf . Accessed 24 July 2017.

4. Moreau P, Masszi T, Grzasko N, et al. Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–34.

5. Bullock JM, Rahman A, Liu Q. Lessons learned: dose selection of small molecule-targeted oncology drugs. Clin Cancer Res. 2016;22(11):2630–8.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contribution of post-transplantation therapy to sustained MRD negativity in multiple myeloma: a retrospective analysis;International Journal of Hematology;2023-12-16

2. Organoboronic acids/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope;Journal of Enzyme Inhibition and Medicinal Chemistry;2023-06-15

3. Dose Titration of Ixazomib Maintenance Therapy in Transplant‐Ineligible Multiple Myeloma: Exposure–Response Analysis of the TOURMALINE‐MM4 Study;Clinical Pharmacology & Therapeutics;2023-05-23

4. New trends in synthetic drugs and natural products targeting 20S proteasomes in cancers;Bioorganic Chemistry;2023-04

5. Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK ‐positive NSCLC;Clinical and Translational Science;2022-02-08